A micellar cisplatin prodrug simultaneously eliminates both cancer cells and cancer stem cells in lung cancer. (5th June 2017)

• Record Type: Journal Article
• Authors: Zhu, Yan-Hua; Sun, Chun-Yang; Shen, Song; Khan, Malik I. U.; Zhao, Yang-Yang; Liu, Yang; Wang, Yu-Cai; Wang, Jun
• Is Part Of: Biomaterials science. Volume 5:Number 8(2017:Aug.)
• Page Start: 1612
• Page End: 1621
• Publication Date: 2017-06-05
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1039/c7bm00278e
• Languages: English
• ISSNs: 2047-4830

Abstract

Abstract : Cancer stem cells and bulk cancer cells can be simultaneously targeted when using nanomedicine. Abstract : Platinum-based chemotherapy as first-line treatment for lung cancers encounters insufficient selectivity, severe side effects and drug resistance in clinics. In this study, we developed an amphiphilic prodrug of cisplatin-poly(ethylene glycol)- block -polycaprolactone and demonstrated that the prodrug formed micellar nanoparticles, NPPt(IV), with an average diameter of ∼100 nm. NPPt(IV) released platinum in response to the intracellular acidic and reductive environment, and in turn induced significant anti-proliferative activity in lung cancer cells. More importantly, NPPt(IV) exhibited a prominent inhibitory effect on CD133 + lung cancer stem cells (CSCs) and suppressed tumor growth in vivo . Unlike cisplatin treatment which eventually enriches CSCs, NPPt(IV) treatment prevents the accumulation of CD133 + lung CSCs in tumors. Therefore, NPPt(IV) simutaneously targeting CSCs and non-CSCs might represent a superior strategy to improve conventional anticancer therapy directed predominantly to tumor bulk populations.